Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2022 07:15 ET | Source: Graybug Vision, Inc.

Graybug to Present at the 2022 OIS Retina Innovation Summit

BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
April 13, 2022 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision Appoints Dirk Sauer to Board of Directors

BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
August 04, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
May 12, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
May 12, 2021 07:00 ET | Source: Graybug Vision, Inc.

Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMD

GB-102 1mg has shown competitive durability and anatomical control versus afliberceptTrend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patientsDeveloping...
May 05, 2021 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision to Report Full-Data Analysis of the 12-month Treatment Phase of its Phase 2b ALTISSIMO Trial

REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
March 09, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial

Median time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...
March 04, 2021 17:04 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
February 17, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in SVB Leerink Global Healthcare Conference

REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
February 01, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...

Next Page keyboard_arrow_right